Cas:959238-46-1 3-Isobutylmorpholine hydrochloride manufacturer & supplier

Chemical Name:3-Isobutylmorpholine hydrochloride

CAS.NO:959238-46-1

Synonyms:3-isobutylmorpholine hydrochloride;3-(2-methylpropyl)morpholine hydrochloride

Molecular Formula:C₈H₁₈ClNO

Molecular Weight:179.68800

HS Code:2934999090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:197.2ºC at 760 mmHg

Density:0.87g/cm3

Index of Refraction:1.423

PSA:21.26000

Exact Mass:179.10800

LogP:2.15170

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 3-isobutylmorpholine hydrochloride chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3-(2-methylpropyl)morpholine hydrochloride physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3-(2-methylpropyl)morpholine hydrochloride Use and application,3-(2-methylpropyl)morpholine hydrochloride technical grade,usp/ep/jp grade.

Related News: Fate Therapeutics, Inc. recently announced new in vivo preclinical data for FT819, its first off-the-shelf, iPSC-derived chimeric antigen receptor (CAR) T-cell product candidate, at the 61st American Society of Hematology (ASH) Meeting and Exposition in Orlando, FL. 3-Isobutylmorpholine hydrochloride manufacturer Biogen has said that some 1.5 million Americans with early-stage Alzheimer’s will be eligible for the drug, priced at an average of $56,000 per year, with the federal Medicare insurance program for seniors likely on the hook for most of the cost. 3-Isobutylmorpholine hydrochloride supplier Biogen has said that some 1.5 million Americans with early-stage Alzheimer’s will be eligible for the drug, priced at an average of $56,000 per year, with the federal Medicare insurance program for seniors likely on the hook for most of the cost. 3-Isobutylmorpholine hydrochloride vendor Due to the cyclic nature of the upstream chemical products of the API, it is expected that the impact of price fluctuations of raw materials on the performance of API companies is unavoidable, but companies with thick product lines and the ability to produce intermediates are expected to minimize the upstream price impact. 3-Isobutylmorpholine hydrochloride factory Fate Therapeutics, Inc. recently announced new in vivo preclinical data for FT819, its first off-the-shelf, iPSC-derived chimeric antigen receptor (CAR) T-cell product candidate, at the 61st American Society of Hematology (ASH) Meeting and Exposition in Orlando, FL.